Unigestion Holding’s Regeneron Pharmaceuticals REGN Stock Holding History

Unigestion Holding’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-246	Closed	-$205K	–	189
2023 Q3	$205K	Sell	246 -649	-73%	-$510K	0.01%	186
2023 Q2	$634K	Buy	895 +28	+3%	+$21.6K	0.04%	150
2023 Q1	$704K	Hold	867	–	–	0.04%	162
2022 Q4	$625K	Buy	+867	New	+$640K	0.03%	189
2021 Q2	–	Sell	-7,271	Closed	-$3.44M	–	250
2021 Q1	$3.44M	Sell	7,271 -9,359	-56%	-$4.56M	0.12%	80
2020 Q4	$8.03M	Buy	16,630 +13,246	+391%	+$7.15M	0.28%	58
2020 Q3	$1.89M	Buy	+3,384	New	+$2.05M	0.07%	91

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Unigestion Holding's REGN Position: Q4 2023 in Review

Unigestion Holding sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 246 shares — an estimated $205K sold.

Unigestion Holding first reported a position in REGN in Q3 2020 and held it in 7 quarters. The position peaked at $8.03M in Q4 2020. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Unigestion Holding reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Unigestion Holding sold 246 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $205K.
Unigestion Holding first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Unigestion Holding's Regeneron Pharmaceuticals position peaked at $8.03M in Q4 2020.
1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Unigestion Holding's 13F filing for Q4 2023, filed 14 Feb 2024.